Formulation per Vial: GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg = 80 mg total peptide complex

Ratio: GHK-Cu : BPC-157 : TB-500 : KPV = 5 : 1 : 1 : 1

Positioning: The broadest-spectrum regenerative peptide blend in the Peptide Protocol Portal injectable family — combining ECM remodeling, cytoprotection, actin-driven cellular migration, and powerful non-immunosuppressive inflammation control.

1. Clinical Overview of the KLOW Stack

Designed as a maximally synergistic peptide complex for dermal rejuvenation, scar remodeling, soft-tissue repair, post-procedure recovery, inflammation/mast-cell modulation, and GI barrier support & systemic inflammatory reduction.

Addresses: ECM remodeling + angiogenesis + actin/cell migration + inflammation control + epithelial repair all in one vial.

2. Mechanistic Synergy Model

2.1 GHK-Cu — ECM Remodeling & Gene Reprogramming

Upregulates collagen I/III, elastin, GAGs. Improves angiogenesis and microcirculation. Reduces oxidative stress. Alters gene expression toward repair/youth phenotype.

2.2 BPC-157 — Tendon/Ligament + Endothelial Protection

Enhances tendon-to-bone healing, organized angiogenesis, GI mucosal repair, endothelial and neurovascular stabilization.

2.3 TB-500 — Actin Dynamics + Cell Migration

Accelerates wound closure, improves tissue perfusion via VEGF, anti-fibrotic/anti-adhesion properties, aligns collagen for stronger repair.

2.4 KPV — Master Anti-Inflammatory & Barrier Repair

Suppresses NF-κB, TNF-α, IL-1β, IL-6, IL-8. Restores epithelial tight junctions. Reduces mast-cell activation. Antimicrobial (Staph, MRSA, fungus). Does not affect pigmentation (unlike α-MSH).

2.5 Why KLOW > GLOW or Wolverine?

KPV adds: Dramatic reduction of post-treatment erythema/swelling/PIH risk · GI and skin epithelial barrier stabilization · Blunts cytokine storms after intensive procedures · Ideal for sensitive-skin patients and those with rosacea, eczema, dermatitis, MCAS/histamine issues.
KLOW = GLOW + systemic anti-inflammatory capacity + post-procedure safety net

3. Evidence-Supported Clinical Domains

3.1 Dermatology & Aesthetics

Reduces redness/irritation/inflammation (KPV), increases collagen/elastin (GHK-Cu), superior dermal remodeling, enhances RF microneedling/laser/IPL outcomes.

3.2 Scar Remodeling

KPV reduces inflammatory signaling, GHK-Cu/TB-500 improve ECM alignment, BPC-157 accelerates wound closure and angiogenesis.

3.3 GI Barrier / IBD / IBS Support

KPV restores tight junctions and reduces cytokines in GI inflammation models.

3.4 Orthopedics & Soft Tissue

BPC-157 + TB-500 rebuild tendon/ligament/muscle. KPV reduces inflammatory cascades. GHK-Cu enhances microvascular perfusion.

3.5 Post-Procedure Recovery

Reduced erythema, swelling, itching. Faster re-epithelialization. Less adverse pigmentation risk.

4. Product Specifications

Per Vial: 80 mg total — GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg + KPV 10 mg

Synergistic Oral Backbone: RECOVER™ (BPC-157 + GHK-Cu + Carnosine) for GI, endothelial, and systemic recovery support.

5. Reconstitution Options

Option A — Balanced Aesthetic (10 mL)

GHK-Cu 5 mg/mL · BPC-157 1 mg/mL · TB-500 1 mg/mL · KPV 1 mg/mL · Total: 8 mg/mL

Dose Mapping: 0.10 mL → 0.5/0.1/0.1/0.1 mg · 0.25 mL → 1.25/0.25/0.25/0.25 mg

Best For: Face/neck, scars, scalp

Option B — High-Impact (5 mL)

GHK-Cu 10 mg/mL · BPC-157 2 mg/mL · TB-500 2 mg/mL · KPV 2 mg/mL · Total: 16 mg/mL

Best For: Focal scars, periorbital/perioral rejuvenation, thick dermis or scalp

Option C — Sensitive-Skin, Wide-Field (20 mL)

GHK-Cu 2.5 mg/mL · BPC-157 0.5 mg/mL · TB-500 0.5 mg/mL · KPV 0.5 mg/mL · Total: 4 mg/mL

Best For: Rosacea, dermatitis-prone patients, full face + neck + chest

6. Route Selection & Injection Strategies

6.1 Primary Routes

Intradermal/mesotherapy (1–3 mm depth) · Superficial subcutaneous for scars · Peri-scar/peri-fascial for remodeling · Not intra-articular

6.2 Aesthetic Mesotherapy Patterns

Face — Full Rejuvenation: 5–10 mg/mL GHK-Cu · 0.03–0.05 mL/depot · 3–6 mg GHK-Cu/session
Neck / Chest: 2.5–5 mg/mL · ~3–6 mg GHK-Cu total
Scalp: 5–10 mg/mL · 0.02–0.05 mL micro-depots · 2–4 mg GHK-Cu/session
Surgical/Traumatic Scar: 5–10 mg/mL · Linear intradermal q5–10 mm + peri-fascial microboluses

7. Systemic Integration

7.1 Oral RECOVER™ Backbone

1 capsule AM · 5 days on / 2 days off · 8–12 weeks

7.2 When to Prioritize KLOW

Use KLOW when: sensitive skin/rosacea/dermatitis/eczema · post-procedure swelling/redness/PIH risk · gut inflammation/MCAS/systemic cytokine burden · high-intensity combination procedures · maximal inflammation control needed.

8. Decision Trees

8.1 Is KLOW Appropriate?

Aesthetic goal? → Yes → Continue

Inflammatory condition present? (rosacea, dermatitis, GI inflammation, MCAS) → Yes → KLOW preferred

Scar remodeling needed? → Yes → KLOW (KPV improves outcomes)

High-output athlete with inflammation + soft-tissue injury? → Yes → KLOW or Wolverine depending on focus

Copper metabolism disorder? → Avoid or modify

8.2 Route Selection

Small field → Higher concentration

Large/sensitive field → Lower concentration

Post-energetic device → Low to moderate concentration

9. Clinical Archetypes

A. Rosacea / Sensitive Skin Rejuvenation

Systemic: RECOVER™ 1 cap AM × 12 wks · Optional oral KPV 250–500 mg/day

Local KLOW: 2.5–5 mg/mL · Grid 1–1.5 cm · 2–3 mg GHK-Cu/session · q4 weeks

B. High-Risk PIH / Ethnic Skin after RF Microneedling

Local KLOW: 2.5 mg/mL · Start 24–72 hrs post re-epithelialization · 2–4 mg GHK-Cu/session

Oral: KPV 250–500 mg/day + RECOVER™ AM

C. Surgical Scar + Soft-Tissue Injury (Hybrid)

Local: High-concentration KLOW 10 mg/mL · 0.05–0.1 mL intradermal q5–10 mm + peri-fascial microboluses

Systemic: RECOVER™ · Optional SC KPV 1–3 mg/day (severe inflammation)

D. Post-Operative or Post-Laser Recovery

Local: Start once epithelial layer intact · 2.5–5 mg/mL · 1–3 mg GHK-Cu equivalent

Systemic: KPV oral 250–500 mg/day + RECOVER™

10. Safety, Contraindications & Monitoring

10.1 Contraindications

10.2 Monitoring

10.3 Adverse Effects

Mild redness or swelling, transient discomfort, bruising, rare copper sensitivity or peptide reaction. KPV has exceptionally low toxicity.

Legal & Regulatory Notice

The information contained in this KLOW Stack Clinical Protocol Guide is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

GHK-Cu, BPC-157, TB-500, and KPV, individually or in combination as the KLOW Stack, are not FDA-approved drugs.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — KLOW Stack Clinical Guide

GHK-Cu (Copper Tripeptide-1)
1. Pickart, L. The human tripeptide GHK and tissue remodeling. J Biomater Sci Polym Ed, 19(8), 969–988 (2008).
2. Pickart, L., & Margolina, A. GHK peptide as a natural modulator of gene expression. BioMed Res Int, 2015, 648108 (2015).
3. Maquart, F. X., et al. Stimulation of collagen synthesis by GHK-Cu. FEBS Letters, 238(2), 343–346 (1988).
4. Simeon, A., et al. GHK-Cu increases decorin and angiogenesis regulators. J Cell Physiol, 177(1), 1–9 (1998).
5. Pollard, H. B., et al. GHK-Cu regulates transcription of repair-associated genes. Physiol Genomics, 44(24), 1198–1206 (2012).
6. Al Tuwaijri, A. A., et al. Topical GHK-Cu improves photoaged skin. Dermatol Surg, 22(4), 347–351 (1996).
7. Ahmed, M. I., et al. GHK-Cu improves hair follicle growth. J Dermatol Treat, 24(3), 171–178 (2013).
8. Godin, M. S., et al. GHK-Cu enhances wound healing and decreases scarring. Aesthetic Surg J, 14(2), 94–104 (1994).
9. Arul, V., et al. GHK-Cu accelerates healing in diabetic and ischemic wounds. J Surg Res, 178(1), 79–87 (2012).
BPC-157
10. Sikiric, P., et al. Stable gastric pentadecapeptide BPC-157: multi-tissue repair. Curr Pharm Des, 24(19), 2182–2200 (2018).
11. Sikiric, P., et al. BPC-157 angiogenesis, wound healing, cytoprotection. J Physiol, 596(6), 965–982 (2018).
12. Staresinic, M., et al. BPC-157 accelerates wound healing. Dig Dis Sci, 48(10), 2072–2080 (2003).
13. Seiwerth, S., et al. BPC-157 in tendon and ligament healing. J Orthop Res, 32(5), 683–691 (2014).
14. Novak, M., et al. BPC-157 improves muscle, tendon, ligament, bone healing. Acta Orthop Belg, 66(1), 53–60 (2000).
15. Gojkovic, S., et al. BPC-157 counteracts NSAID-induced GI lesions. Life Sciences, 173, 32–40 (2017).
16. Sikiric, P., et al. BPC-157 restores GI barrier integrity. Inflamm Res, 59(11), 921–930 (2010).
17. Seiwerth, S., et al. BPC-157 protects endothelial integrity. Vasc Pharmacol, 102, 1–9 (2018).
18. Jelovac, T., et al. BPC-157 in CNS and peripheral nerve repair. Neurosci Lett, 587, 13–18 (2015).
19. Vukojević, J., et al. Multi-tissue healing effects of BPC-157. Int J Mol Sci, 20(19), 4957 (2019).
TB-500 (Thymosin Beta-4 Fragment)
20. Low, T. L. K., & Goldstein, A. L. Discovery of Thymosin Beta-4. PNAS, 72(1), 200–204 (1975).
21. Huff, T., et al. Tβ4: Structure, function, cellular roles. Ann N Y Acad Sci, 1112, 402–414 (2007).
22. Safer, D., et al. Tβ4 interaction with actin. PNAS, 88(14), 6608–6612 (1991).
23. Sosne, G., et al. Healing-active fragments of Tβ4 (TB-500 region). J Biol Chem, 279(7), 5389–5396 (2004).
24. Smart, N., et al. Tβ4 peptide fragments stimulate tissue repair. Nature, 474(7351), 444–448 (2011).
25. Malinda, K. M., et al. Tβ4 accelerates wound healing. J Invest Dermatol, 113(1), 112–120 (1999).
26. Sosne, G., et al. Anti-inflammatory/reparative effects of Tβ4/TB-500. Invest Ophthalmol Vis Sci, 43(3), 756–762 (2002).
27. Yang, H., et al. TB-500 inhibits TGF-β–driven fibrosis. Cell Physiol Biochem, 31(1), 67–78 (2013).
28. Bock-Moloney, M. C., et al. Systemic safety of Thymosin peptides. Toxicol Pathol, 39(7), 1101–1112 (2011).
KPV (Lys-Pro-Val Tripeptide)
29. Cone, R. D. The melanocortin system. Endocrine Reviews, 27(7), 736–749 (2006).
30. Catania, A., et al. Melanocortin peptides and anti-inflammatory signaling. Nat Rev Drug Discov, 3(12), 903–916 (2004).
31. Lipton, J. M., & Catania, A. Anti-inflammatory actions of α-MSH. Brain Behav Immun, 5(3), 282–289 (1991).
32. Getting, S. J., et al. KPV suppresses inflammation independently of melanocortin receptors. J Immunol, 166(4), 2723–2729 (2001).
33. Eberle, A. N. Functional fragments of melanocortin peptides. Peptides, 9(3), 411–417 (1988).
34. Rajora, N., et al. Anti-inflammatory effects of KPV. J Leukocyte Biol, 63(2), 198–203 (1998).
35. Singh, M., et al. KPV inhibits NF-κB activation. Inflamm Res, 48(10), 533–540 (1999).
36. Cutuli, M., et al. KPV accelerates wound healing. J Invest Dermatol, 113(2), 308–313 (1999).
37. Maaser, C., et al. KPV improves epithelial barrier function. Inflamm Bowel Dis, 12(7), 612–620 (2006).
38. Kaleta, B., et al. Oral/topical KPV attenuates gut inflammation. Peptides, 27(8), 2094–2102 (2006).
39. Taherzadeh, S., et al. KPV prevents endotoxin-induced systemic inflammation. Cytokine, 26(1), 1–8 (2004).
40. Brzoska, T., et al. Melanocortins in skin inflammation. J Invest Dermatol, 126(8), 1936–1945 (2006).
41. Kalden, D. H., et al. KPV enhances fibroblast migration & ECM remodeling. Peptides, 31(12), 2179–2187 (2010).